Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 901–1,000 of 1,001
Hickish, T., Mehta, A. O., Liu, M.-C., Huang, C., Arora, R. S., Chang, Y., Yang, Y., Vladimirov, V. I., Jain, M. M., Tsang, J. W. H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06449-4 · Cited by 17
Moloney, C., & Shiely, F. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.03.011 · Cited by 19
Zhukova, L., Andreeva, I. I., Эдуардовна, З. Л., Дильшодович, З. А., Королева, И. А., Витальевич, Н. А., Палтуев, Р. М., Parokonnaia, A. A., Петровский, А. В., Portnoi, S. M., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.1.200823 · Cited by 19
Dey, P., Joshi, M., Mujawar, A., Malhotra, R., & De, A. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00693-6 · Cited by 14
Schlam, I. M., Nunes, R., & Lynce, F. C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s272197 · Cited by 14
Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics
Ketchemen, J. P., Babeker, H., Tikum, A. F., Nambisan, A. K., Njotu, F. N., Nwangele, E., & Fonge, H. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02272-4 · Cited by 15
Ligorio, F., Zambelli, L., Bottiglieri, A., Castagnoli, L., Zattarin, E., Lobefaro, R., Ottini, A., Vingiani, A., Pupa, S. M., Bianchi, G., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006960 · Cited by 15
Tumor Heterogeneity in Breast Cancer
Badve, S., & Gökmen‐Polar, Y. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000074 · Cited by 23
Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine
Fazekas, J., Fürdös, I., Singer, J., & Jensen‐Jarolim, E. (2016) · Oncology Letters · doi:10.3892/ol.2016.5001 · Cited by 16
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
Kourié, H. R., Rassy, E., Clatot, F., de Azambuja, E., & Lambertini, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s122397 · Cited by 14
Network science in clinical trials: A patient-centered approach
Manem, V. S., Salgado, R., Aftimos, P. G., Sotiriou, C. P., & Haibe‐Kains, B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.006 · Cited by 15
Recent advances in the medical treatment of breast cancer
Vorobiof, D. (2016) · F1000Research · doi:10.12688/f1000research.9619.1 · Cited by 13
Hildebrand, K. M., Singla, A. K., McNeil, R., Marritt, K., Hildebrand, K., Zemp, F. J., Rajwani, J., Itani, D. M., Bose, P., Mahoney, D. J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253864 · Cited by 17
Young Women with Breast Cancer: The Current Role of Precision Oncology
Srikanthan, A., Awan, A. A., McGee, S. F., & Rushton, M. K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111620 · Cited by 14
Seo, J., Koh, J., Lee, D., Kim, J., Ryu, H. S., Lee, K.-H., Kim, T. Y., & Im, S. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01746-w · Cited by 13
Şahin, T. K., Akyıldız, A., Doğan, O. T., Kavgacı, G., Güven, D. C., & Aksoy, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070824 · Cited by 15
A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options
Tsuruta, S., Ogata, D., Namikawa, K., Nakano, E., & Yamazaki, N. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae103 · Cited by 13
Antonini, M., Mattar, A. P. L., Pinheiro, D. J. P. D. C., Maia, I. B., Teixeira, M. D., Amorim, A. G., Ferraro, O., de Oliveira, L. C., Ramos, M. D. N. M., Cavalcante, F. P., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104417 · Cited by 16
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
Yu, A. F., Dang, C. T., Moskowitz, C. S., Meza, A. M., DeFusco, P. A., Oligino, E. J., Chen, C. L., Sanford, R. A., Drullinsky, P. R., Bromberg, J., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.05.006 · Cited by 13
Corti, D., & Kearns, J. D. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.001 · Cited by 13
Lavaud, P., Rousseau, B., Ajgal, Z. C., Arrondeau, J., Huillard, O., Alexandre, J., Lesne-Hulin, A., & Goldwasser, F. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3798-8 · Cited by 13
Han, Y., Wang, J., Liu, W., Yuan, P., Li, Q., Zhang, P., Ma, F., Luo, Y., Fan, Y., Chen, S., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s198962 · Cited by 14
Hopkins, A. M., Rowland, A., McKinnon, R. A., & Sorich, M. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00789 · Cited by 13
Schmid, S., Klingbiel, D., Aebi, S. P., Goldhirsch, A., Mamot, C., Munzone, E., Nolè, F., Oehlschlegel, C., Pagani, O., Pestalozzi, B. C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6105-3 · Cited by 13
Yamashita, T., Kawaguchi, H., Masuda, N., Kitada, M., Narui, K., Hattori, M., Yoshinami, T., Matsunami, N., Yanagihara, K., Kawasoe, T., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00991-6 · Cited by 13
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer
Tu, Z., Schmoellerl, J., Mariani, O., Zheng, Y., Hu, Y. P., Vincent‐Salomon, A., & Karnoub, A. E. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00259-z · Cited by 13
Rugo, H. S., Pennella, E. J., Gopalakrishnan, U., Bronchud, M. H., Herson, J., Koch, H. F., Loganathan, S., Deodhar, S. S., Marwah, A., Manikhas, A., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06197-5 · Cited by 13
Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours
Rădulescu, L., Rădulescu, D., Ciuleanu, T., Crișan, D., Buzdugan, E., Romitan, D.-M., & Buzoianu, A. D. (2021) · Medicina · doi:10.3390/medicina57080806 · Cited by 15
Beagan, J. J., Drees, E. E. E., Stathi, P., Eijk, P. P., Meulenbroeks, L., Kessler, F. L., Middeldorp, J. M., Pegtel, D. M., Zijlstra, J. M., Sie, D., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.08.008 · Cited by 14
Can Systems Biology Advance Clinical Precision Oncology?
Rocca, A., & Kholodenko, B. Ν. (2021) · Cancers · doi:10.3390/cancers13246312 · Cited by 16
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
Chung, W., Huang, W.-L., Liao, W., Hung, C.-H., Chiang, C., Cheung, C. H. A., & Su, W. (2022) · Scientific Reports · doi:10.1038/s41598-021-04328-y · Cited by 14
Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy
Niwińska, A., Pogoda, K., Jagiełło-Gruszfeld, A., & Duchnowska, R. (2022) · Cancers · doi:10.3390/cancers14040965 · Cited by 14
Müller, V., Hein, A., Hartkopf, A. D., Fasching, P. A., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.015 · Cited by 15
Biosimilar monoclonal antibodies in China: A patent review
Liu, J., Yang, Y.-H., Wu, N., & Wei, J. (2022) · Bioengineered · doi:10.1080/21655979.2022.2090206 · Cited by 15
Wu, Y., Li, L., Zhang, D., & Ma, F. (2022) · Cancers · doi:10.3390/cancers14194551 · Cited by 13
Shah, A. N., Santa-Maria, C. A., Mukhija, D., Shah, N. C., Kang, A. K., Kumthekar, P., Burdett, K. B., Chandra, S., Chang, J. C., Tsarwhas, D., et al. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.12.006 · Cited by 15
Bono, A., Monica, G. L., Alamia, F., Mingoia, F., Gentile, C., Peri, D., Lauria, A., & Martorana, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813769 · Cited by 13
Niraula, S., & Ocaña, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.011 · Cited by 13
Pertuzumab for the treatment of breast cancer
Robert, M., Frenel, J., Bourbouloux, E., Rigaud, D. B., Patsouris, A., Augereau, P., Gourmelon, C., & Campone, M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596805 · Cited by 16
Self-citationXu, X., Luo, C., Cao, B., Xu, R., Wang, F., Wei, X., Zhang, T., Han, L., & Zhang, D. (2019) · Molecules · doi:10.3390/molecules24213949 · Cited by 13
Takahashi, K., Ishibashi, E., Kubo, T., Harada, Y., Hayashi, H., Kano, M., Shimizu, Y., Shirota, H., Mori, Y., Muto, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000021457 · Cited by 13
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
Haji, F., & Hurvitz, S. A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.06.012 · Cited by 14
Danese, M. D., Masaquel, A. S., dos Santos, E. C. S., Brammer, M. G., Lee, A. P., & Lalla, D. (2015) · Value in Health · doi:10.1016/j.jval.2015.06.003 · Cited by 13
Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer
Lees, C., Yazdan-Ashoori, P., Jerzak, K. J., & Gandhi, S. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0285 · Cited by 13
Küemmel, S., Harper-Wynne, C. L., Park, Y. H., Franke, F. A., Laurentiis, M. D., Schumacher-Wulf, E., Eiger, D., Heeson, S., Cardona, A. F., Özyılkan, Ö., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12179-9 · Cited by 14
Self-citationde Azambuja, E., Piccart, M. J., Fielding, S., Townend, J., Hillman, D. W., Colleoni, M., Roylance, R. R., Kelly, C. M., Lombard, J. M., El-Abed, S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103938 · Cited by 14
Self-citationAdvances in Medical Management of Early Stage and Advanced Breast Cancer: 2015
Witherby, S. M., Rizack, T., Sakr, B. J., Legare, R. D., & Sikov, W. M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.09.005 · Cited by 13
Dias, A., Claudino, W. M., Sinha, R. J., Perez, C. A., & Jain, D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.015 · Cited by 14
Viale, G., Paterson, J. C., Bloch, M., CSATHY, G. S., Allen, D., Dell’Orto, P., Kjærsgaard, G., Levy, Y. Y., & Jørgensen, J. T. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.002 · Cited by 12
Martin, N., Isambert, N., Gomez‐Roca, C., Goeldner, R.-G., Zanetta, S., Sadrolhefazi, B., de Mont-Serrat, H., Campone, M., & Delord, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3689-2 · Cited by 12
Self-citationSoares, L. R., Freitas‐Júnior, R., Curado, M. P., Paulinelli, R. R., Martins, E., & Oliveira, J. C. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00408 · Cited by 16
Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer
Kjær, I. M., Olsen, D. A., Brandslund, I., Bechmann, T., Jakobsen, E. H., Bogh, S. B., & Madsen, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-72944-1 · Cited by 13
Daniels, B. J., Kiely, B. E., Tang, M., Houssami, N., Lord, S. J., & Pearson, S. (2021) · The Breast · doi:10.1016/j.breast.2021.05.001 · Cited by 12
Olaleye, O., Spanov, B., Ford, R., Govorukhina, N. I., van de Merbel, N. C., & Bischoff, R. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02807 · Cited by 12
Matusz‐Fisher, A., & Tan, A. R. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1981284 · Cited by 16
Veitch, Z. W. N., Ribnikar, D., Tilley, D. G., Tang, P. A., King, K. M., Bedard, P. L., Lupichuk, S., & Cescon, D. W. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01676-4 · Cited by 13
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
Chiec, L. S., & Kumthekar, P. (2022) · CNS Drugs · doi:10.1007/s40263-021-00894-x · Cited by 13
Dai, W. F., Beca, J. M., Nagamuthu, C., Liu, N., de Oliveira, C., Earle, C. C., Trudeau, M., Mercer, R. E., & Chan, K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.45460 · Cited by 12
Li, Y., Wu, L., Liu, Y., Ma, S., Huang, B., Feng, X., & Wang, H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101424 · Cited by 13
Liedtke, C., Thill, M., Hanf, V., & Schütz, F. (2015) · Breast Care · doi:10.1159/000431248 · Cited by 12
Yang, C., Khwaja, R., Tang, P. A., Nixon, N. A., King, K. M., & Lupichuk, S. (2022) · Current Oncology · doi:10.3390/curroncol29060337 · Cited by 12
Noorlandt, H. W., Stoevelaar, R., van Dongen, S. I., Arslan, M., Luu, N., Kranenburg, L. W., Witkamp, E., van der Rijt, C. C. D., Lorig, K. R., van der Heide, A., et al. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13638 · Cited by 20
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 17
Padmanabhan, R., Kheraldine, H., Gupta, I., Meskin, N., Hamad, A. A., Vranić, S., & Moustafa, A. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.977664 · Cited by 12
Shagisultanova, E. I., Gradishar, W. J., Brown-Glaberman, U. A., Chalasani, P., Brenner, A. J., Stopeck, A., Parris, H. J., Gao, D., McSpadden, T., Mayordomo, J. I., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0117 · Cited by 14
Maïo, M. D., Bighin, C., Schettini, F., Ruelle, T., Marandino, L., Fabi, A., Angelis, C. D., Giuliano, M., Placido, P. D., Laurentiis, M. D., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.103583 · Cited by 13
Arkenau, H., Italiano, A., Mak, G., Toulmonde, M., Baird, R. D., García-Corbacho, J., Plummer, R., Flynn, M., Forster, M. D., Wilson, R. H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.134 · Cited by 12
Lupichuk, S., Cheung, W. Y., & Stewart, D. A. (2019) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223419879429 · Cited by 12
Prognostic factors and outcome of HER2+ breast cancer with CNS metastases
Masci, G., Agostinetto, E., Giordano, L., Bottai, G., Torrisi, R., Losurdo, A., Sanctis, R. D., Navarria, P., Scorsetti, M., Zuradelli, M., et al. (2020) · Future Oncology · doi:10.2217/fon-2019-0602 · Cited by 12
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer
Schneeweiß, A., Bauerfeind, I., Fehm, T. N., Janni, W., Thomssen, C., Witzel, I., Wöckel, A., Müller, V., & on behalf of the Commission Breast of the Working Group Gynecologic Oncology (AGO) (2020) · Breast Care · doi:10.1159/000511925 · Cited by 12
Shi, D., Bai, J., Chen, Y., Wang, X., Zhang, Y., & Liu, H. (2020) · BioMed Research International · doi:10.1155/2020/1068202 · Cited by 12
Regulatory barriers to the advancement of precision medicine
Pettitt, D., Smith, J. A., Meadows, N. A., Arshad, Z., Schuh, A., DiGiusto, D. L., Bountra, C., Holländer, G. A., Barker, R., & Brindley, D. A. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1176526 · Cited by 16
Shimura, M., Gosho, M., & Hirakawa, A. (2017) · Statistics in Medicine · doi:10.1002/sim.7258 · Cited by 13
Daniels, B. J., Kiely, B. E., Tang, M., Tervonen, H. E., & Pearson, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6126-y · Cited by 12
Kolářová, I., Vaňásek, J., Odrážka, K., Melichar, B., Ryška, A., Petera, J., Vošmik, M., & Doležel, M. (2019) · Biomedical Papers · doi:10.5507/bp.2019.060 · Cited by 12
Wang, X., Lee, K. S., Zeng, X., Sun, T., Im, Y., Li, H., Wang, K., Zhou, P., Li, V., Chen, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105852 · Cited by 11
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
Kaehler, M., & Cascorbi, I. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_639 · Cited by 11
Giordano, G., Griguolo, G., Landriscina, M., Meattini, I., Carbone, F., Leone, A., Re, M. D., Fogli, S., Danesi, R., Colamaria, A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104185 · Cited by 14
Jin, N., Xu, Y., Wang, S., Sun, C., Yan, X., Yang, F., Liang, Y., Chen, W., & Huang, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.10.004 · Cited by 11
Nishimura, R., Fujiki, Y., Taira, T., Miyaki, T., Kanemitsu, S., Yotsumoto, D., Teraoka, M., Kawano, J., Gondo, N., Mitsueda, R., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.02.013 · Cited by 11
Sun, H., Kang, E. Y., Chen, H., Sweeney, K. J., Suchko, M., Wu, Y., Wen, J., Krishnamurthy, S., Albarracin, C. T., Ding, Q., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07256-3 · Cited by 11
Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care
Weide, R., Feiten, S., Wassmann, C., Rendenbach, B., Braun, U., Burkhard, O., Ehscheidt, P., & Schmidt, M. (2024) · Cancers · doi:10.3390/cancers16071255 · Cited by 14
Dannehl, D., von Au, A., Engler, T., Volmer, L. L., Gutsfeld, R., Englisch, J. F., Hahn, M., Hawighorst‐Knapstein, S., Chaudhuri, A., Bauer, A., et al. (2024) · Cancers · doi:10.3390/cancers16081490 · Cited by 11
Hu, L., Zhang, S., Sienkiewicz, J., Zhou, H., Berahovich, R., Sun, J., Li, M., Ocampo, A., Liu, X., Huang, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12070808 · Cited by 15
Wang, R., Smyth, L. M., Iyengar, N. M., Chandarlapaty, S., Modi, S., Jochelson, M. S., Patil, S. N., Norton, L., Hudis, C. A., & Dang, C. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0512 · Cited by 11
Advances in EGFR/HER2-directed clinical research on breast cancer
Chow, L. W., Lie, E. F., & Toi, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.009 · Cited by 11
Current Biomarkers for Precision Medicine in Breast Cancer
Ahn, S. K., & Jung, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_18 · Cited by 13
The management of HER2‐positive early breast cancer: Current and future therapies
Chen, J., Colosimo, M. L., & Lim, E. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13655 · Cited by 12
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe
Vokinger, K. N., & Kesselheim, A. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00561-6 · Cited by 11
Pizzuti, L., Krasniqi, E., Sperduti, I., Barba, M., Gamucci, T., Mauri, M., Veltri, E. M., Meattini, I., Berardi, R., Lisa, F. S. D., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059873 · Cited by 11
Xu, H., Zhang, H., Guo, W. Q., Zhong, X. Z., Sun, J., Zhang, T., Wang, Z., & Ma, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10015-6 · Cited by 11
Altena, R., Bajalica‐Lagercrantz, S., & Papakonstantinou, A. (2022) · Cancers · doi:10.3390/cancers14194665 · Cited by 15
Cheng, W.-J., Lin, S., Chuang, K., Chen, M. J., Ho, H., Chen, L.-C., Hsieh, C., & Sheu, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s388066 · Cited by 11
Xu, W., Jiang, Y., Xu, L., Li, C., Ji, W., Liu, Z., Xue, D., Gu, Y., Zhong, Z., He, S., et al. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad009 · Cited by 11
Miliotou, Α. N., Georgiou‐Siafis, S. K., Ntenti, C., Pappas, I. S., & Papadopoulou, L. C. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110576 · Cited by 12
ABC3 Consensus: Assessment by a German Group of Experts
Thomssen, C., Augustin, D., Ettl, J., Haidinger, R., Lück, H., Lüftner, D., Marmé, F., Marschner, N. W., Müller, L., Overkamp, F., et al. (2016) · Breast Care · doi:10.1159/000443515 · Cited by 11
Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
Kotecki, N., Gombos, A., & Awada, A. H. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1613892 · Cited by 11
Michel, L. L., Hartkopf, A. D., Fasching, P. A., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wallwiener, M., et al. (2020) · Cancers · doi:10.3390/cancers12103021 · Cited by 14
Younis, T., Lee, A., Coombes, M., Bouganim, N., Becker, D., Révil, C., & Jhuti, G. S. (2020) · Current Oncology · doi:10.3747/co.27.6517 · Cited by 12
Veeraraghavan, J., Gutiérrez, C., Sethunath, V., Mehravaran, S., Giuliano, M., Shea, M. J., Mitchell, T., Wang, T., Nanda, S., Pereira, R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00274-0 · Cited by 11
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.